Stock Traders Purchase Large Volume of CymaBay Therapeutics Call Options (NASDAQ:CBAY)

CymaBay Therapeutics, Inc. (NASDAQ:CBAYGet Free Report) was the recipient of some unusual options trading on Wednesday. Stock investors acquired 7,136 call options on the company. This represents an increase of approximately 423% compared to the average daily volume of 1,365 call options.

CymaBay Therapeutics Price Performance

Shares of CBAY stock opened at $24.39 on Friday. The stock’s 50-day moving average is $22.44 and its 200 day moving average is $17.20. CymaBay Therapeutics has a 1-year low of $7.26 and a 1-year high of $25.37. The company has a debt-to-equity ratio of 0.32, a current ratio of 22.76 and a quick ratio of 22.76. The company has a market cap of $2.77 billion, a P/E ratio of -26.51 and a beta of 0.30.

CymaBay Therapeutics (NASDAQ:CBAYGet Free Report) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.02). During the same quarter last year, the firm earned ($0.28) EPS. Research analysts predict that CymaBay Therapeutics will post -0.95 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. William Blair restated an “outperform” rating on shares of CymaBay Therapeutics in a report on Tuesday, November 14th. Cantor Fitzgerald raised their target price on shares of CymaBay Therapeutics from $23.00 to $24.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 8th. Piper Sandler boosted their price target on CymaBay Therapeutics from $19.00 to $33.00 and gave the company an “overweight” rating in a report on Monday, November 6th. Lifesci Capital reissued an “outperform” rating on shares of CymaBay Therapeutics in a research note on Tuesday, December 26th. Finally, Raymond James lifted their target price on CymaBay Therapeutics from $33.00 to $34.00 and gave the company a “strong-buy” rating in a research report on Wednesday, November 8th. One investment analyst has rated the stock with a sell rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $22.64.

View Our Latest Stock Report on CymaBay Therapeutics

Insider Activity

In related news, CEO Sujal Shah sold 64,865 shares of the business’s stock in a transaction dated Monday, December 11th. The stock was sold at an average price of $20.00, for a total value of $1,297,300.00. Following the sale, the chief executive officer now directly owns 171,301 shares in the company, valued at $3,426,020. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, CEO Sujal Shah sold 64,865 shares of the stock in a transaction that occurred on Monday, December 11th. The stock was sold at an average price of $20.00, for a total transaction of $1,297,300.00. Following the completion of the transaction, the chief executive officer now directly owns 171,301 shares in the company, valued at approximately $3,426,020. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Daniel Menold sold 21,497 shares of the business’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $21.99, for a total transaction of $472,719.03. The disclosure for this sale can be found here. Insiders sold a total of 164,439 shares of company stock worth $3,470,441 over the last 90 days. Corporate insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On CymaBay Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. raised its stake in CymaBay Therapeutics by 1.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 48,669 shares of the biopharmaceutical company’s stock valued at $1,150,000 after buying an additional 525 shares during the last quarter. Alps Advisors Inc. raised its position in shares of CymaBay Therapeutics by 1.1% in the 3rd quarter. Alps Advisors Inc. now owns 72,461 shares of the biopharmaceutical company’s stock valued at $1,080,000 after purchasing an additional 783 shares during the last quarter. Strategic Blueprint LLC raised its position in shares of CymaBay Therapeutics by 6.3% in the 3rd quarter. Strategic Blueprint LLC now owns 16,800 shares of the biopharmaceutical company’s stock valued at $250,000 after purchasing an additional 1,000 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in CymaBay Therapeutics by 96.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,516 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 1,238 shares in the last quarter. Finally, Arizona State Retirement System grew its position in CymaBay Therapeutics by 8.4% during the 3rd quarter. Arizona State Retirement System now owns 22,212 shares of the biopharmaceutical company’s stock worth $331,000 after purchasing an additional 1,716 shares during the last quarter. Hedge funds and other institutional investors own 95.03% of the company’s stock.

CymaBay Therapeutics Company Profile

(Get Free Report)

CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of autoimmune liver disease, primary biliary cholangitis (PBC).

Further Reading

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.